Professeur, Faculté de médecine et des sciences de la santé
FMSS Dép. médecine nucléaire et radiobiologie
(2013) Post-doctorate (Pharmaceutical sciences). University of Toronto.
(2008) Engineered Antibody Fragments for the Targeting and Imaging of Prostate Stem Cell Antigen (PSCA)-Expressing Xenografts In Vivo by microPET. Doctorate (Molecular and Medical Pharmacology). University of California, Los Angeles.
(2002) Thermodynamic principles of protein folding. Bachelor's Honours (Biochemistry). University of California, Santa Barbara.
Antibodies, Biological and Biochemical Mechanisms, Cancer Diagnosis and Detection, Cancer of the Urinary System, Development of Drug Delivery Systems, Leukemia.
Biochemistry, Cell Biology, Chemistry, Molecular Biology, Physics.
Antibodies (functionalization - engineering), Antibody conjugation chemistry (cargo attachment), Endosome escape mechanism for antibodies, Intracellular trafficking control, Life science and health applications, Multidisciplinary (chemistry-biology-physics).
The antibody-conjugate field has made significant progress recently owing to careful optimization of several parameters, including drug potency, linker technology, and the stoichiometry and placement of conjugated drugs. However, these technological progresses have only marginally improved survival rates in humans with cancer. This is due to the current antibody-conjugates inability to overcome multiple cellular mechanisms that reduce drug cellular accumulation and leads to resistance. . We have discovered and patented a technology that functionalizes antibodies allowing them to overcome the mechanisms causing reduced drug accumulation. We apply this technology to improve the accumulation of radioisotope, photosensitizers, and chemotherapeutics to more accurately identify and kill cancer cells. Currently we focus on the targeting of leukemic stem cells and muscle invasive bladder cancer (MIBC) cells.
Centre de recherche du CHUS
Anglais, Français, Espagnol (castillan)